Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-02-13 Sale |
2023-02-14 5:10 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
3,000 | $6.85 | $20,550 | 577,677 (Direct) |
View |
| 2023-01-17 Sale |
2023-01-18 6:10 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
3,000 | $7.04 | $21,120 | 580,677 (Direct) |
View |
| 2022-12-15 Sale |
2022-12-19 4:29 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,602 | $7.5306 | $42,186 | 583,677 (Direct) |
View |
| 2022-08-11 Sale |
2022-08-15 5:40 pm |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
15,000 | $16.75 | $251,250 | 218,271 (Direct) |
View |
| 2022-08-11 Sale |
2022-08-15 5:12 pm |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
15,000 | $16.75 | $251,250 | 218,271 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-02 5:40 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
2,000 | $11.97 | $23,940 | 540,257 (Direct) |
View |
| 2022-07-05 Sale |
2022-07-06 4:16 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
2,000 | $11.44 | $22,880 | 542,257 (Direct) |
View |
| 2022-06-22 Sale |
2022-06-23 4:40 pm |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
10,000 | $11.76 | $117,600 | 233,271 (Direct) |
View |
| 2022-06-21 Sale |
2022-06-22 4:47 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
2,000 | $11.18 | $22,360 | 544,257 (Direct) |
View |
| 2022-05-19 Sale |
2022-05-19 5:40 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
11,500 | $7.3993 | $85,092 | 546,257 (Direct) |
View |
| 2022-03-15 Sale |
2022-03-17 5:59 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
5,169 | $7.709 | $39,848 | 320,119 (Direct) |
View |
| 2022-03-15 Sale |
2022-03-17 5:59 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
8,849 | $7.6802 | $67,962 | 413,841 (Direct) |
View |
| 2022-03-15 Sale |
2022-03-17 5:59 pm |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
23,648 | $7.6488 | $180,879 | 5,202,848 (Indirect Direct) |
View |
| 2022-03-15 Sale |
2022-03-17 5:58 pm |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
11,469 | $7.6337 | $87,551 | 1,253,141 (Indirect Direct) |
View |
| 2022-03-15 Sale |
2022-03-17 5:58 pm |
Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer |
8,698 | $7.6326 | $66,388 | 120,430 (Direct) |
View |
| 2022-01-12 Purchase |
2022-01-14 2:13 pm |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
15,000 | $12.6 | $189,000 | 258,885 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-03-14 Tax Withholding |
2023-03-16 4:46 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
23,628 | $5.67 | 556,049 (Direct) |
View |
| 2023-01-20 Option Award |
2023-01-24 5:02 pm |
N/A 2033-01-20 |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
1,124,923 | $0 | 1,124,923 (Direct) |
View |
| 2022-10-07 Tax Withholding |
2022-10-11 4:35 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D |
8,464 | $11.83 | 541,946 (Direct) |
View |
| 2022-10-07 Option Award |
2022-10-11 4:35 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D |
19,120 | $0 | 541,946 (Direct) |
View |
| 2022-10-03 Tax Withholding |
2022-10-05 4:02 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D |
8,968 | $11.06 | 531,290 (Direct) |
View |
| 2022-07-08 Option Award |
2022-07-12 4:48 pm |
N/A 2032-07-08 |
Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director |
89,815 | $0 | 89,815 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:58 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Humer Franz B Director |
44,178 | $0 | 191,892 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:58 pm |
N/A 2032-06-15 |
Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director |
35,535 | $9.62 | 76,986 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:58 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director |
22,089 | $0 | 76,986 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:58 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
44,178 | $0 | 303,063 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:58 pm |
N/A 2032-06-15 |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
57,624 | $0 | 278,806 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:57 pm |
N/A 2032-06-15 |
Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director |
71,070 | $0 | 71,070 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:57 pm |
N/A 2032-06-15 |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
71,070 | $0 | 71,070 (Direct) |
View |
| 2022-03-31 Other |
2022-04-04 4:44 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | PF Equity Holdings 2 B.V. 10% Owner |
22,032,040 | $0 | 22,032,040 (Direct) |
View |
| 2022-03-14 Other(A) |
2022-04-01 5:40 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
4,710,120 | $0 | 14,502,270 (Indirect) |
View |
| 2022-03-14 Other |
2022-03-31 5:27 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
4,710,121 | $0 | 16,495,448 (Indirect) |
View |
| 2022-03-23 Option Award |
2022-03-25 5:52 pm |
N/A 2032-03-23 |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
605,947 | $0 | 926,066 (Direct) |
View |
| 2022-03-23 Option Award |
2022-03-25 5:51 pm |
N/A 2032-03-23 |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
2,195,512 | $0 | 2,195,512 (Direct) |
View |
| 2022-03-23 Option Award |
2022-03-25 5:51 pm |
N/A 2032-03-23 |
Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer |
737,179 | $0 | 737,179 (Direct) |
View |
| 2022-03-23 Option Award |
2022-03-25 5:50 pm |
N/A 2032-03-23 |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
1,458,333 | $0 | 1,458,333 (Direct) |
View |
| 2022-03-23 Option Award |
2022-03-25 5:49 pm |
N/A 2032-03-23 |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
605,947 | $0 | 1,859,088 (Direct) |
View |
| 2022-03-23 Option Award |
2022-03-25 5:49 pm |
N/A 2032-03-23 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
447,873 | $0 | 861,714 (Direct) |
View |
| 2022-03-07 Other |
2022-03-09 6:26 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
412,618 | $0 | 671,503 (Direct) |
View |
| 2022-03-07 Gift |
2022-03-09 6:26 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
412,618 | $0 | 671,503 (Direct) |
View |
Ownership |
2022-01-21 6:29 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | TPG GP A LLC WINKELRIED JON 10% Owner |
0 | $0 | 18,716,306 (Indirect) |
View |